Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OligoGpivotalCF

Financiado

Cerrado

A pivotal phase IIb clinical trial of inhaled alginate oligosaccharide OligoG...

A pivotal phase IIb clinical trial of inhaled alginate oligosaccharide OligoG for cystic fibrosis The objective of the current proposal is to advance the orphan drug OligoG CF-5/20 (OligoG) through a pivotal phase IIb clinical trial, to enable a new and improved therapeutic approach for the orphan disease cystic fibrosis by 20... ver más

31/12/2022

AlgiPharma

12M€

Presupuesto del proyecto: 12M€

Líder del proyecto

ALGIPHARMA AS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

SC1-PM-08-2017: New therapies for rare diseases

I+D

Cerrada hace 8 años

0% 49% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

AlgiPharma

3.22M€ | Lider

IMPERIAL COLLEGE OF SCIENCE...

79.99K€ | Participante

INNOTECH VISION

52.26K€ | Participante

BUNDESMINISTERIUM FUER GESUN...

32.50K€ | Participante

Proyectos interesantes

IMPACTT

Medical Technol...

Biomedical Imag...

7M€ Cerrado

SADEL

Medical Technol...

Nanotechnology

6M€ Cerrado

CTQ2012-32929

Medical Technol...

Nanotechnology

125K€ Cerrado

PRO-CF-MED

Medical Technol...

Biotechnology

21M€ Cerrado

PTQ2018-009737

Medical Technol...

Biomedical Imag...

83K€ Cerrado

MONAGEL

Medical Technol...

Nanotechnology

175K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2017-12-05
Fecha Fin: 2022-12-31

Líder del proyecto

ALGIPHARMA AS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 12M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The objective of the current proposal is to advance the orphan drug OligoG CF-5/20 (OligoG) through a pivotal phase IIb clinical trial, to enable a new and improved therapeutic approach for the orphan disease cystic fibrosis by 2024. The study drug is an alginate oligosaccharide derived from seaweed. Several properties relevant to the treatment of CF have been demonstrated using in vitro and ex vivo model systems including release of stagnant mucus, disruption of bacterial biofilm and increased bacterial susceptibility to antibiotics. OligoG received an EU Orphan Drug Medicinal Product Designation in 2007 and an FDA Orphan Drug Designation February 2016, for the treatment of cystic fibrosis. The planned clinical trial will include approx 200 CF patients from approx. 35 European sites in coordination with the European Clinical Trial Network. The final study design, selection criteria, procedures and endpoints will be based on results from a recently finalized phase II study and will follow scientific advice and protocol assistance sought at the European Medicines Agency (EMA). A set of clinical and exploratory endpoints will be defined to assess the various effects of OligoG, comprising lung function assessed by spirometry and Lung Clearance Index (LCI) measurements, infection status assessed by frequency of pulmonary exacerbations and non-culture-dependent microbiology, and patient reported outcomes assessed by questionnaires, including standardised CF questionnaires (CFQ-R). A successful trial will enable preparation of international applications for conditional marketing authorisation (cMAA) throughout Europe and a New Drug Application (NDA) in the US, for the treatment of cystic fibrosis lung disease. In accordance with the work programme, a successful project will thus imply a new and improved therapeutic approach within cystic fibrosis available for CF patients by 2024.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores